Summary of Key Points
In 2025, a girl with a rare disease named "Xiaomei" from Shanghai passed away after undergoing brain gene editing treatment. This incident exposed three systemic issues within the gene therapy industry: inadequate ethical review processes, non-compliant fund management, and a fragile industry ecosystem. Xiaomei's parents paid nearly 6 million yuan to support the research (some of which ended up in the researcher's personal account). Pre-trial animal toxicity tests indicated risks of liver and kidney damage, but the ethics committee approved the treatment without reviewing these findings. The incident caused a shock within the industry, leading to a withdrawal of capital, researchers hesitating to conduct further trials, and patients' families facing a dilemma of fearing both the dangers of the treatments and the lack of available options. As a result, the entire gene therapy industry is grappling with a crisis of trust and developmental challenges.
Detailed Analysis
1. Why Did the "Safety Gatekeepers" Fail?
The ethics committee acts as the safety checkpoint for trials, supposed to prevent dangerous experiments from proceeding. However, in this case, it was virtually non-existent:
- Failure to Review Critical Risk Reports: The final animal toxicity report was not available at the time of approval (it later revealed liver damage in four monkeys and kidney damage in one). This was equivalent to allowing a vehicle on the road without checking its brakes.
- Experts Either Didn't Understand or Didn't Dare to Question: Brain gene editing is a highly complex field, and many ethics committee members may not have understood the details. Additionally, since the initiative came from a renowned professor, the committee members were reluctant to raise any concerns, turning the review into a mere formality.
- Lack of Follow-up: After approving the trial, the committee took no further action, failing to monitor its progress or require periodic reports until the incident occurred, thus failing to fulfill their role in providing ongoing supervision.
2. Were the Parents' 6 Million Yuan in Research Funding Used Compliantly?
It is not illegal for families of patients with rare diseases to fund research, but the handling of this case was clearly non-compliant:
- Money Went into Personal Accounts: $130,000 was directly transferred to the researcher's personal account, whereas regulations require that funds be channelled through official hospital or foundation accounts (similar to donating to a school and not directly to a teacher).
- Contradictions with Informed Consent Forms: The consent forms signed by the parents stated that no additional fees would be charged, yet they actually spent 6 million yuan and received gifts such as Apple products and Moutai. With this amount of money involved, researchers might have been hesitant to disclose the risks accurately.
- **Vague "Shareholdings Promises": The researcher claimed that contributions would result in shares, which could lead researchers to deviate from the purpose of treating diseases and instead pursue profits through the research.
3. The Gene Therapy Industry: From a Hot Topic to a Cold One
Gene therapy was once a favored area for investment, but now it is on the brink of stagnation:
- Withdrawal of Capital: Previous incidents, such as the He Jiankui case and safety accidents, have already dampened interest in the industry. This latest incident has further scared investors, who are wary of stricter regulations and project delays. Without funding, companies may not be able to survive.
- Chain Reaction in the Industry: Without corporate funding, CDMOs (contract manufacturing organizations) that produce drugs lose orders, researchers hesitate to conduct trials, and the entire chain comes to a halt.
- Disruption of Innovation: With limited financing channels for early-stage projects in China, many innovative efforts are eliminated before they can even be tested, akin to young plants being trampled underfoot.
4. The Dilemma of Patients' Families
Patients with rare diseases already face a lack of effective treatments, and gene therapy represented their last hope. However, now:
- Fear of Experimental Risks: The Xiaomei incident has filled families with fear, preventing them from allowing their children to participate in trials.
- Lack of Treatment Options: Researchers are cautious about conducting trials due to potential risks, and if companies stop, patients lose any chance of treatment. This situation is more despairing than facing the unknown consequences of the treatments themselves.
- Helplessness of Industry Professionals: Some say that if companies struggle to survive, patients have even fewer options for medical care, highlighting the dual crisis faced by both the industry and its patients.
5. The Way Forward for the Industry
The problems cannot be solved with a one-size-fits-all approach; regulation and development must go hand in hand:
- Strengthening Ethical Review Processes: Experts with technical expertise should be involved, and reviews should be thorough, with regular monitoring of trial progress.
- Standardizing Fund Management: Clear guidelines should establish how family contributions can be used, ensuring that funds are only channelled through official entities.
- Allowing for Compliant Research: Regulatory authorities should not halt all trials due to a single incident, distinguishing between non-compliant practices and legitimate innovation.
- Patient Capital Investment: Gene therapy research requires long-term funding, and investors need to be patient, recognizing the long development cycles involved.
Just as other industries have gradually regulated themselves after experiencing similar challenges, we must also work to address these issues. We cannot give up on a promising field just because of initial setbacks. After all, patients with rare diseases are still waiting for hope.
This analysis not only covers the core aspects of the incident but also explains the key issues in plain language, making it accessible to non-experts.